Letters Section Editor: Stephen J. Lurie,
MD, PhD, Senior Editor.
In Reply: We agree with Dr Killestein and colleagues
that there are several reasons why our results may differ from those of their
brief trial among older patients with multiple sclerosis. These include not
only study design, degree and duration of exposure to cannabinoids, and dose
and contents of the cannabinoid preparations, but also route of administration
and ages of the participants. Nonetheless, we believe that the most important
difference is that we studied healthy participants with a history of cannabinoid
use. By contrast, Killestein et al1 examined
patients with longstanding multiple sclerosis, a disease related to immune
Pacifici R, Zuccaro P, Pichini S, et al. Long-term Use of Hydroxyurea for Sickle Cell Anemia—Reply. JAMA. 2003;290(6):754. doi:10.1001/jama.290.6.754-a
Browse and subscribe to JAMA Network podcasts!
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: